<DOC>
	<DOCNO>NCT03029390</DOCNO>
	<brief_summary>Pre diabetes ( PD ) term refers alteration glucose homeostasis , include impaired fasting glucose ( IFG ) , Imparied glucose tolerance ( IGT ) , involve high risk develop type 2 diabetes mellitus ( T2DM ) 10 year . The efficacy pharmacotherapy prevention diabetes adult prediabetes demonstrate , first line pharmacology treatment metformin , hand , traditional Chinese Ayurverica medicine offer potential active substance treatment hyperglucemia like berberine . Berberine extract hypoglycemic effect animal model well clinical trial type 2 diabetes mellitus even compare metformin , reason compare 's activity metformin prediabetes would provide impact information new alternative treatment compare standard pharmacological treatment . The aim study evaluate effect administration berberine versus metaformine glycemic control , insulin secretion insulin sensitivity patient pre diabetes . The investigator hypothesis administration berberine versus metformin modifies glycemic control , insulin sensitivity insulin secretion patient prediabetes .</brief_summary>
	<brief_title>Effect Berberine Versus Metformin Glycemic Control , Insulin Sensitivity Insulin Secretion Prediabetes</brief_title>
	<detailed_description>A randomized , double-blind , placebo-controlled clinical trial 28 patient diagnosis prediabetes ( IFG IGT ) accordance American Diabetes Association treatment . They assign randomly two group 14 patient , one group receive 850 mg metformin twice day ( breakfast dinner ) one pill placebo ( lunch ) 14 week . There run period , start dose 500 mg first week , second week increase 1000 mg third fourteenth week dose 1500 mg . The group receive 500 mg berberine three time day ( one mealtime ) for14 week . There run period , start dose 850 mg first week , second week dose 850 mg metformin plus one placebo pill third week fourteenth week dose 1700 mg ( two 850 mg metformin pill ) plus one placebo pill . They measure fast blood glucose , postprandial glucose level glycosylated hemoglobin , calculate Area Under Curve glucose insulin , total insulin secretion ( Insolinogenic index ) , first-phase insulin secretion ( Strumvoll index ) insulin sensitivity ( Matsuda index ) . This protocol 's already approve local ethic committee write informed consent 's go obtained volunteer . Statistical analysis present measure central tendency dispersion , average deviation standard quantitative variable ; frequency percentage qualitative variable . Qualitative variable analyze X2 , use difference inter-group Mann-Whitney U Test Wilcoxon Test within-groups difference . It consider statistical significance p≤0.05 .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients sexes Age 31 60 year Diagnosis prediabetes accord 2 ADA criterion ( fast blood glucose level 100125 mg/dl postprandial blood glucose level oral glucose tolerance test 75 oral glucose 140199 mg/dl ) Body Mass Index 25 34.9kg/m2 Informed consent sign Women confirm suspected pregnancy Women lactation and/or puerperium Hypersensibility ingredients intervention Physical impossibility take pill Known uncontrolled renal , hepatic , heart thyroid diseased Diabetes diagnosis Previous treatment glucose Body Mass Index ≥35 kg/m2 Glycosylated hemoglobin &gt; 6.5 % Triglycerides ≥500 mg/dL Total cholesterol ≥240 mg/dL Low density lipoprotein ( cLDL ) ≥190 mg/dL Blood Pressure ≥140/90 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prediabetes</keyword>
	<keyword>hyperglycemia</keyword>
	<keyword>Impaired Fasting Glucose</keyword>
	<keyword>Metformin</keyword>
	<keyword>Berberine</keyword>
	<keyword>glucose intolerance</keyword>
</DOC>